ReShape Lifesciences RSLS Stock
ReShape Lifesciences Price Chart
ReShape Lifesciences RSLS Financial and Trading Overview
| ReShape Lifesciences stock price | 0.37 USD |
| Previous Close | 2.35 USD |
| Open | 2.3 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 800 |
| Day's Range | 2.14 - 2.32 USD |
| 52 Week Range | 2.14 - 40 USD |
| Volume | 128.06K USD |
| Avg. Volume | 260.97K USD |
| Market Cap | 6.47M USD |
| Beta (5Y Monthly) | 1.451408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
RSLS Valuation Measures
| Enterprise Value | -1982564 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.8730159 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.5838443 |
| Price/Book (mrq) | 0.75110966 |
| Enterprise Value/Revenue | -0.179 |
| Enterprise Value/EBITDA | 0.086 |
Trading Information
ReShape Lifesciences Stock Price History
| Beta (5Y Monthly) | 1.451408 |
| 52-Week Change | -93.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 40 USD |
| 52 Week Low | 2.14 USD |
| 50-Day Moving Average | 2.54 USD |
| 200-Day Moving Average | 7.97 USD |
RSLS Share Statistics
| Avg. Volume (3 month) | 260.97K USD |
| Avg. Daily Volume (10-Days) | 49.94K USD |
| Shares Outstanding | 2.94M |
| Float | 2.79M |
| Short Ratio | 1.19 |
| % Held by Insiders | 5.61% |
| % Held by Institutions | 0.92% |
| Shares Short | 103.14K |
| Short % of Float | 3.50% |
| Short % of Shares Outstanding | 3.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -221.84% |
| Gross Margin | 61.40% |
| EBITDA Margin | -206.95% |
Management Effectiveness
| Return on Assets (ttm) | -48.32% |
| Return on Equity (ttm) | -175.75% |
Income Statement
| Revenue (ttm) | 11.09M USD |
| Revenue Per Share (ttm) | 14.61 USD |
| Quarterly Revenue Growth (yoy) | -6.29% |
| Gross Profit (ttm) | 6.8M USD |
| EBITDA | -22945000 USD |
| Net Income Avi to Common (ttm) | -40761000 USD |
| Diluted EPS (ttm) | -87.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.98M USD |
| Total Cash Per Share (mrq) | 3.05 USD |
| Total Debt (mrq) | 86K USD |
| Total Debt/Equity (mrq) | 1.11 USD |
| Current Ratio (mrq) | 2.004 |
| Book Value Per Share (mrq) | 2.929 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19585000 USD |
| Levered Free Cash Flow (ttm) | -10561875 USD |
Profile of ReShape Lifesciences
| Country | United States |
| State | CA |
| City | San Clemente |
| Address | 1001 Calle Amanecer |
| ZIP | 92673 |
| Phone | 949 429 6680 |
| Website | https://www.reshapelifesciences.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 40 |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Q&A For ReShape Lifesciences Stock
What is a current RSLS stock price?
ReShape Lifesciences RSLS stock price today per share is 0.37 USD.
How to purchase ReShape Lifesciences stock?
You can buy RSLS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ReShape Lifesciences?
The stock symbol or ticker of ReShape Lifesciences is RSLS.
Which industry does the ReShape Lifesciences company belong to?
The ReShape Lifesciences industry is Medical Devices.
How many shares does ReShape Lifesciences have in circulation?
The max supply of ReShape Lifesciences shares is 11.74M.
What is ReShape Lifesciences Price to Earnings Ratio (PE Ratio)?
ReShape Lifesciences PE Ratio is now.
What was ReShape Lifesciences earnings per share over the trailing 12 months (TTM)?
ReShape Lifesciences EPS is -13.83 USD over the trailing 12 months.
Which sector does the ReShape Lifesciences company belong to?
The ReShape Lifesciences sector is Healthcare.
ReShape Lifesciences RSLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}